This $629,992 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting Carogen Corp, a minority-owned biopharmaceutical company, to test the safety and efficacy of CARG-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic hepatitis B virus.
The funding will enable Carogen to leverage its exclusive license with Yale University for its replicating viral vector technology platform to advance the development of this novel vaccine candidate. This 1-year award, commencing on September 1, 2024, is part of Carogen's broader research efforts to develop innovative immunotherapies and treatments for chronic viral infections using nucleic acid delivery and immunomodulatory approaches.
Generated 1/28/25, 10:09 AM